Bio-Techne Corporation’s Stock Price Takes a Dip, Falling to $76.91 – A Decrease of 2.29%

Bio-Techne Corporation (TECH)

76.91 USD -1.80 (-2.29%) Volume: 1.33M

Bio-Techne Corporation’s stock price is currently valued at 76.91 USD, experiencing a dip of -2.29% this trading session with a trading volume of 1.33M, yet showing a year-to-date growth of +4.89%, highlighting its resilient performance in the biotechnology market.

Latest developments on Bio-Techne Corporation

As Bio-Techne Corp (NASDAQ: TECH) prepares to announce its second quarter fiscal 2025 financial results on February 5, 2025, investor interest is on the rise. Riverbridge Partners LLC recently disclosed a $49.47 million position in the company, while Fort Washington Investment Advisors Inc. OH has boosted its holdings in Bio-Techne. The upcoming earnings call is expected to provide key financial updates that could impact the stock price movement. In other news, ScaleReady has announced a G-Rex® grant awarded to BrainChild Bio, a development that could further bolster Bio-Techne’s position in the biotech industry.

Bio-Techne Corporation on Smartkarma

Analysts at Baptista Research have been closely monitoring Bio Techne Corp, a leading life sciences company. In their recent research reports, they highlighted the company’s solid performance in the first quarter of Fiscal Year 2025, with a 4% year-over-year organic revenue growth. This growth was attributed to the stabilization of biopharma end markets and robust execution in areas such as cell and gene therapy. Baptista Research also conducted an independent valuation of the company using a Discounted Cash Flow (DCF) methodology to evaluate factors that could influence the company’s price in the near future.

Furthermore, Baptista Research also delved into Bio Techne Corp‘s enhanced investment in molecular diagnostics, as discussed during the company’s earnings call for the fourth quarter of fiscal year 2024. Despite a complex external environment with reduced biotech funding and budget recalibrations from large pharmaceutical entities and academia, the company reported modest organic revenue growth of 1% year-over-year. The analysts at Baptista Research continue to assess the company’s performance and potential, providing valuable insights for investors on Smartkarma.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio Techne Corp seems to have a positive long-term outlook. The company scores well in momentum, indicating strong market performance and investor interest. Additionally, Bio Techne Corp scores moderately in value and growth, suggesting potential for future profitability and expansion. However, the company’s scores in dividend and resilience are lower, indicating room for improvement in these areas.

Overall, Bio Techne Corp is a company that specializes in developing, manufacturing, and selling biotechnology products and clinical diagnostic controls. With a focus on proteins, cytokines, growth factors, immunoassays, and small molecules, the company plays a significant role in the biotech industry. While there are areas for improvement in terms of dividend and resilience, Bio Techne Corp‘s strong momentum score suggests it may continue to see success in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma